Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

The OncoSignature multiplex immunofluorescence assay received breakthrough device designation from the FDA for identifying patients with endometrial cancer who may benefit from ACR-368 (prexasertib) ...

Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

The rising consumption of processed foods raises serious health concerns, including increased risks of infertility and cancer ...

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that ...